Covalent Modifiers

MARCH 19, 2024

Thus, UCHL1 inhibitors could serve as a viable treatment strategy against these aggressive cancers. Herein, we describe a covalent fragment screen that identified the chloroacetohydrazide scaffold as a covalent UCHL1 inhibitor.

Fragment Screening 195

Fragment Screening Disease Treatment 195

Drug Target Review

APRIL 7, 2025

This receptor is also expressed in the brain, where it helps to regulate dopamine release, making it a therapeutic target for the treatment of insomnia, pain, depression and Parkinson’s disease. This crucial role in regulating vital bodily processes makes it a highly important drug target within GPCR research. References Sun D, et al.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Sygnature Discovery

MARCH 14, 2025

Sygnature Discovery offers high throughput screening along with additional hit identification tools including virtual screening, knowledge-based design, and fragment screening. Sygnature Discovery integrates cutting-edge automation to ensure efficiency and precision in our HTS processes.

Biochemical Assays 52

Biochemical Assays Fragment Screening Computational Chemistry Assay Development 52

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. In terms of compound libraries, we have a high-throughput screening library of about 200,000 ligands. We can screen with many different formats and modalities.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Molecular Design

JANUARY 12, 2021

In the fourth of his rules for air fighting , ‘Sailor’ Malan (readers may also be interested in his insights into fragment screening library design ) asserts that “height gives you the initiative” which can be adapted for drug design as “affinity gives you the initiative”.

Fragment Screening 52

Fragment Screening Treatment Nurses Doctors 52

PerkinElmer

JUNE 3, 2022

Viral protease inhibitors that block enzymes critical for viral replication have long been used in the treatment of human immunodeficiency (HIV) and hepatitis C viruses. Researchers are now studying the potential of protease inhibitors for the treatment of SARS-CoV-2. For research use only. Not for use in diagnostic procedures.

Fragment Screening 52

Fragment Screening Clinical Trials Vaccine Pharmacokinetics 52

Molecular Design

JULY 18, 2020

While I’m not particularly keen on the use of the term ‘open source’ in this context, I have absolutely no quibble with the goal of seeking cures and treatments for diseases that are ignored by commercial drug discovery organizations.

Biochemical Assays 52

Biochemical Assays Fragment Screening Pharmacokinetics Drugs 52